This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Siga Gets Tentative Contract For Smallpox Drug

NEW YORK (AP) â¿¿ Siga Technologies Inc. said Wednesday the U.S. Department of Health and Human Services intends to give it a contract to deliver 1.7 million courses of its smallpox treatment for the Strategic National Stockpile.

Its shares soared 41 percent on the announcement of a contract that could generate as much as $2.8 billion in revenue. The company had only $13.8 million in revenue in 2009.

The contract award depends on the successful resolution of a complaint by a rival for the contract that Siga may not qualify for the award as a small business as defined by the government, the company said.

The company said the contract is pending because competitor Chimerix Inc. filed a protest against Siga's selection because of its size. Chimerex objected after being informed by the Department of Health that it was an unsuccessful bidder. The department designated the proposed contract as a small business set-aside at the time of the original solicitation in March of 2009.

SIGA said intends to respond promptly to the Small Business Administration concerning Chimerix's protest.

The Strategic National Stockpile is a national stockpile of medicines meant for use in the event of a public health emergency.

Siga shares climbed $3.53, or 41 percent, to $12.09 in late morning trading after climbing as high as $12.39 earlier in the session.
Copyright 2010 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs